Get Connected:

The MD Magazine ADHD condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

FDA Approves Liquid Extended-Release Amphetamine for Treatment of ADHD
The FDA has approved Tris Pharma’s extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older.
Rates of attention deficit hyperactivity disorder (ADHD) drop as elevation increases, according to findings published in the Journal of Attention Disorders.
Study results published in the July-August 2015 issue of the Journal of the American Board of Family Medicine suggest a potential association between maternal chemical intolerance and a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in their offspring.
Lisdexamfetamine (Vyvanse), a stimulant usually prescribed to children and adults with attention-deficit/hyperactivity disorder (ADHD), may help to improve menopausal women's executive function, a new, small study suggests.
Children with attention-deficit/hyperactivity disorder (ADHD) often fidget, but new research suggests intense fidgeting may actually help them focus on the task at hand.
Misuse of prescription stimulant medications such as Ritalin and Adderall may begin at an earlier age than previously believed, according to research published in the July 1 issue of Drug and Alcohol Dependence.
Compared to healthy individuals, ADHD patients are 2 times more likely to die prematurely – and the risk is higher in women and girls.

Most Popular

$vacMongoViewPlus$ $vAR$